Yu. А. Ragulin

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

Martin Schüler, James Chih‐Hsin Yang, K. Park et al. · Annals of Oncology · 2015 · 132 citations · Full text

Medicine, Oncology, Pharmacology +13

Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses

Paul Mitchell, N. Thatcher, Mark A. Socinski et al. · Annals of Oncology · 2015 · 107 citations · Full text

Medicine, Oncology, Pharmacology +16

Afatinib monotherapy in patients with metastatic squamous cell carcinoma of the lung progressing after erlotinib/gefitinib (E/G) and chemotherapy: Interim subset analysis from a phase III trial.

Joo-Hang Kim, Francesco Grossi, Filippo de Marinis et al. · Journal of Clinical Oncology · 2012 · 10 citations

Medicine, Oncology, Pharmacology +16